Trials / Terminated
TerminatedNCT00870155
A Study for Patients With Multiple Sclerosis
An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 546 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To obtain additional safety data in subjects who have previously completed the MBP8298-01 study "A Double Blind Placebo Controlled Multi-Centre to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Multiple Sclerosis" Dirucotide is generic name for MBP8298.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dirucotide | 500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-03-27
- Last updated
- 2010-09-09
Locations
10 sites across 10 countries: Canada, Denmark, Estonia, Finland, Germany, Latvia, Netherlands, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00870155. Inclusion in this directory is not an endorsement.